TOP HEADLINES

Featured Story

  • Health agencies inform on Zika vaccine timeline

    Multiple public health authorities have given insight to the timing of Zika vaccine development, with the WHO now stating that any vaccine may be too late for the current outbreak, a similar situation to the one the world experienced in the Ebola epidemic.

Valneva scores $42M supply contract with DOD

Valneva currently markets Ixiaro, a Japanese encephalitis vaccine and Dukoral, the cholera vaccine it acquired from Johnson & Johnson in 2015. Now, the Lyon, France-based vaccine maker is building on its relationship with the U.S. Department of Defense with a new $42 million supply contract for Ixiaro.

Analyst: Mitsubishi Tanabe's tobacco-based flu jab could have 'significant impact' on market

Following Mitsubishi Tanabe's announcement that its tobacco-based flu vaccine could hit the market by 2018 or 2019, a GlobalData analyst has lauded the Japanese company's candidate as poised to "take over" the flu vaccine market from traditional egg-based vaccines.

Duke, NIAID track HIV evolution with eyes on creating a vaccine

A team led by the Duke Human Vaccine Institute and the National Institute of Allergy and Infectious Diseases has tracked the evolution of HIV and the body's corresponding immune response, hoping now to turn the knowledge gained into an experimental vaccine.

Novavax explores Zika vaccine R&D effort as virus continues to spread

Vaccine companies and research organizations worldwide continue to race against Zika, with a new entrant emerging in Novavax. The biotech announced it's conducting preliminary Zika research in a week that saw several other developments in the field.

Sanofi digs into details on hastened Zika effort

Just last month, Sanofi became the first Big Pharma player to enter the Zika vaccine R&D space as its peers calculated their responses and weighed their options. Now, the French pharma is taking it a step further, outlining its plans to devote dozens of scientists to the field in a move aimed at expediting its vaccine development.

MORE NEWS

From Our Sister Sites

FierceMarkets Network
  • FierceBiotech
  • FierceBiotechIT
  • FierceBiotechResearch
  • FierceDrugDelivery
  • FierceMedicalDevices
  • FierceVaccines
  • FiercePharma
  • FiercePharmaAsia
  • FiercePharmaManufacturing
  • FierceCRO
  • FierceDiagnostics
  • FiercePharmaMarketing
  • FierceAnimalHealth
  • More Fierce Network sites
FierceBiotech
Lilly CEO's Korean tour sparks rumors of a biosimilars deal with Samsung

Eli Lilly CEO John Lechleiter is shaking hands around South Korea this week as part of a tour of Asia, and one stop, at the biologics-focused Samsung Bioepis, has stirred speculation that the American drugmaker might be scouting for a partnership.

FierceMedicalDevices
J&J highlights consumer devices, most investable 6 device segments in quest for growth

After cutting deep into its medical device business early this year with a major restructuring, Johnson & Johnson recently offered a cheerier vision. At the Barclays Global Healthcare Conference on March 17, it highlighted a consumer medical device focus, particularly in emerging markets, alongside 6 device areas of innovation that are expected to undergird growth in the segment for the conglomerate going forward in comments.